IV期非小细胞肺癌手术切除范围与局部区域复发及生存的关系:两家三级转诊中心的结果
本研究纳入1996至2023年两家胸外科中心因IV期非小细胞肺癌行肺切除的179例患者,按切除范围分为亚肺叶、肺叶及大于肺叶切除三组。
要点
- IV期NSCLC肺切除后局部区域复发总体为13.4%。
- 切除范围(亚肺叶、肺叶、大于肺叶)不独立预测局部区域复发。
- 各组总生存与无进展生存相似,切除范围不影响生存结局。
核心结论
- IV期非小细胞肺癌的切除范围不影响后续局部区域复发,也未见总生存或无进展生存的组间差异。
研究设计与样本
- 回顾性队列研究,纳入两家胸外科部门1996至2023年因IV期非小细胞肺癌行肺切除的患者共179例,按切除范围分为亚肺叶、肺叶及大于肺叶三组。
主要发现
- 179例患者平均年龄58.8岁(四分位距51.8-66.5岁),平均转移灶数目1.68个(四分位距1.0-2.0)。
- 116例(64.8%)接受新辅助治疗,其中22例(12.3%)达完全缓解。
- 手术方式:亚肺叶切除31例(17.3%),肺叶切除130例(72.6%),大于肺叶切除18例(10.1%)。
- 局部区域复发共24例(13.4%),亚肺叶组2例(6.4%)、肺叶组20例(15.4%)、大于肺叶组2例(11.1%)。
临床怎么用
- 对于合适的IV期非小细胞肺癌患者,选择亚肺叶、肺叶或更大范围切除时,无需以降低局部区域复发为主要考量。
- 应着重识别与转移性疾病手术患者最佳肿瘤学结局相关的指南。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The benefits of pulmonary resection as local consolidative therapy for stage IV non-small cell lung cancer (NSCLC) have been clearly demonstrated in appropriate patients. For early-stage disease, debate continues regarding the role of anatomic versus parenchymal-sparing resection. We explored the impact of resection extent on outcomes for stage IV NSCLC. METHODS: Patients were identified from 2 thoracic surgery departments. Included patients underwent pulmonary resection for stage IV NSCLC between 1996 and 2023. Resection extent was categorized as sublobar, lobar, or greater than lobar. The primary outcome was development of locoregional recurrence (adjacent to the surgical margin, ipsilateral hemithorax, or regional lymph nodes). A multivariable binomial logistic regression was performed for locoregional recurrence. Kaplan-Meier analyses evaluated survival outcomes. RESULTS: In total, 179 patients were included, with mean age of 58.8 years (interquartile range, 51.8-66.5 years). The mean number of metastases was 1.68 (interquartile range, 1.0-2.0). A total of 116 (64.8%) patients received neoadjuvant treatment, with 22 (12.3%) achieving complete response, and 31 (17.3%) patients underwent sublobar resection, 130 (72.6%) lobectomy, and 18 (10.1%) more extensive resections. Locoregional recurrence occurred in 24 (13.4%) patients, including 2 (6.4%) in the sublobar group, 20 (15.4%) lobectomy group, and 2 (11.1%) greater-than-lobectomy group. Extent of resection did not independently predict locoregional recurrence (sublobar resection odds ratio, 0.44, P = .30; greater than lobar odds ratio, 0.48, P = .51). Overall (P = .14) and progression-free survival (P = .35) were similar between groups. CONCLUSIONS: Resection extent in stage IV NSCLC does not impact subsequent locoregional recurrence, highlighting the importance of identifying relevant guidelines for optimal oncologic outcomes in patients undergoing surgery for metastatic disease.
引用
- Eisenberg MA, Werner R, Ries S, et al. Extent of resection in surgically resected stage IV non-small cell lung cancer: Results from two tertiary referral centers. J Thorac Cardiovasc Surg. 2025. PMID: 40280541. doi:10.1016/j.jtcvs.2025.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。